{
  "run_id": "RUN_20260204_132700_1fed028ce5fb",
  "timestamp": "2026-02-04T15:03:34.091951",
  "document": "03_Marketing_WINREVAIR EU Expansion.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/03_Marketing_WINREVAIR EU Expansion.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 3,
  "total_validated": 3,
  "total_rejected": 0,
  "total_investigational": 1,
  "drugs": [
    {
      "matched_text": "sotatercept",
      "preferred_name": "Sotatercept",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "drug_class": null,
      "mechanism": null,
      "development_phase": "ACTIVE_NOT_RECRUITING",
      "sponsor": null,
      "conditions": [
        "Multiple Myeloma"
      ],
      "nct_id": "NCT01562405",
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": null,
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "NCT",
          "code": "NCT01562405",
          "display": null
        }
      ],
      "context": "NEWS RELEASE\n\nMerck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)\n\n2025-12-12\n\nRAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: ",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_investigational_drugs.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "WINREVAIR",
      "preferred_name": "sotatercept-csrk",
      "brand_name": "WINREVAIR",
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": "INJECTABLE",
      "route": "INJECTION",
      "marketing_status": "Prescription",
      "codes": {
        "rxcui": null,
        "mesh": null,
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "FDA_NDA",
          "code": "BLA761363",
          "display": null
        }
      ],
      "context": "NEWS RELEASE\n\nMerck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)\n\n2025-12-12\n\nRAHWAY, N.J.--(BUSINESS WIRE)--",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_fda_approved_drugs.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "prostacyclin",
      "preferred_name": "Prostacyclin",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": "D011464",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "RxCUI",
          "code": "8814",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D011464",
          "display": "Epoprostenol"
        }
      ],
      "context": " signs of capillary and/or venous involvement. Participants were on background PAH treatment, 72% on triple therapy, 28% on double therapy and 59% on prostacyclin infusion therapy. There were more participants in WHO FC III (74%) compared to WHO FC IV (26%). The REVEAL Lite 2 risk score was <9 for 2% of partici",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_lexicon_drug.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Prostaglandins I",
        "carboprostacyclin",
        "HOE 892"
      ],
      "pubtator_normalized_name": "Epoprostenol",
      "enrichment_source": "pubtator3"
    }
  ]
}